RT Journal Article
SR Electronic
T1 A genome epidemiological study of SARS-CoV-2 introduction into Japan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.01.20143958
DO 10.1101/2020.07.01.20143958
A1 Tsuyoshi Sekizuka
A1 Kentaro Itokawa
A1 Masanori Hashino
A1 Tetsuro Kawano-Sugaya
A1 Rina Tanaka
A1 Koji Yatsu
A1 Asami Ohnishi
A1 Keiko Goto
A1 Hiroyuki Tsukagoshi
A1 Hayato Ehara
A1 Kenji Sadamasu
A1 Masakatsu Taira
A1 Shinichiro Shibata
A1 Ryohei Nomoto
A1 Satoshi Hiroi
A1 Miho Toho
A1 Tomoe Shimada
A1 Tamano Matsui
A1 Tomimasa Sunagawa
A1 Hajime Kamiya
A1 Yuichiro Yahata
A1 Takuya Yamagishi
A1 Motoi Suzuki
A1 Takaji Wakita
A1 Makoto Kuroda
A1 COVID-19 Genomic Surveillance Network in Japan
YR 2020
UL http://medrxiv.org/content/early/2020/07/02/2020.07.01.20143958.abstract
AB Background After the first case of COVID-19 in Japan on 15 January 2020, multiple nationwide COVID-19 clusters were identified by the end of February. The Japanese government focused on mitigating emerging COVID-19 clusters by conducting active nationwide epidemiological surveillance. However, an increasing number of cases appeared until early April, many with unclear infection routes exhibiting no recent history of travel outside Japan. We aimed to evaluate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome sequences from COVID-19 cases until early April and characterise the genealogical networks to demonstrate possible routes of spread in Japan.Methods Nasopharyngeal specimens were collected from patients and a quantitative reverse transcription polymerase chain reaction testing for SARS-CoV-2 was performed. Positive RNA samples were subjected whole genome sequencing and a haplotype network analysis was performed.Findings Some of the primary clusters identified during January and February in Japan directly descended from Wuhan-Hu-1-related isolates in China and other distinct clusters. Clusters were almost contained until mid-March; the haplotype network analysis demonstrated that COVID-19 cases from late March through early April may have caused an additional large cluster related to the outbreak in Europe, leading to additional spread within Japan. National self-restraint during February was effective in mitigating the COVID-19 spread, but late action on stopping immigration and declaring national emergency in Japan might be involved in the later increase in cases.Interpretation Genome surveillance suggested that at least two distinct SARS-CoV-2 introductions from China and other countries occurred.Funding Japan Agency for Medical Research and Development.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study is not a clinical trial. Not available.Clinical Protocols https://www.gisaid.org/epiflu-applications/next-hcov-19-app/ Funding StatementThis study was supported by a Grant-in Aid from the Japan Agency for Medical Research and Development (AMED) under Grant number JP20fk0108103, JP19fk0108103 and JP19fk0108104.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the National Institute of Infectious Diseases in Japan (Approval No. 1091). It was conducted according to the principles of the Declaration of Helsinki, in compliance with the Law Concerning the Prevention of Infections and Medical Care for Patients of Infections of Japan. The ethical committee waived the need for written consent since the study involved the viral genome sequencing. The personal data related to the clinical information were anonymised, and our procedure is to not request written consent for all patients with COVID-19.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe new sequences have been deposited in Global Initiative on Sharing All Influenza Data (GISAID) with accession IDs EPI_ISL_479792 to EPI_ISL_480227 (Table S2). https://www.gisaid.org/epiflu-applications/next-hcov-19-app/